Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03073473Terminated

Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

Role: lead

NCT02671045Terminated

Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer

Role: lead

NCT03328052Phase 4Unknown

MYnd Analytics Directed Therapy in Depression

Role: lead

All 3 trials loaded